Background Idiopathic pulmonary fibrosis (IPF) pathogenesis involves multiple pathways,
and combined antifibrotic therapy is needed for future IPF therapy. Inhaled interferon-γ (IFN …

Pirfenidone is an orally active small molecule that has been shown to inhibit the progression
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …

Background Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary
fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in …

Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …

Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although
the precise cause of the disease is still unknown, recent studies have shown that the …

Pirfenidone, a broad-spectrum antifibrotic agent, is known to have efficacy in certain fibrotic
disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We …

Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor
prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently …

Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease, largely unresponsive to treatment
with corticosteroids and immunosuppressives. The aim of this randomized, prospective …

Background and objective Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease
with poor prognosis. Activated fibroblasts are the key effector cells in fibrosis, producing …